GW Pharmaceuticals plc (NASDAQ:GWPH)

CAPS Rating: 3 out of 5

GWPH News and Commentary

Caps

How do you think GWPH will perform against the market?

Add Stock to CAPS Watchlist

All Players

169 Outperform
20 Underperform
 

All-Star Players

35 Outperform
9 Underperform
 

Wall Street

1 Outperform
1 Underperform
 

Top GWPH Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

goldguru (< 20)
Submitted October 26, 2015

CBD healing power just being proven to the world. GWPH well-positioned as first mover in this space.

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

GWPH VS S&P 500 (SPY)

Fools bullish on GWPH are also bullish on:

Fools bearish on GWPH are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about GWPH.

Recs

0
Member Avatar heretic001 (< 20) Submitted: 4/29/2018 3:01:45 AM : Outperform Start Price: $136.92 GWPH Score: +6.23

Cannabis meds

Recs

0
Member Avatar Bigsef77 (70.46) Submitted: 4/17/2018 10:59:08 AM : Outperform Start Price: $121.39 GWPH Score: -6.91

Marijuana-based drug gets positive review from US agency

WASHINGTON (AP) — A closely watched medicine made from the marijuana plant reduces seizures in children with severe forms of epilepsy and warrants approval in the United States, health officials said Tuesday.

British drugmaker GW Pharmaceuticals is seeking permission to sell its purified form of an ingredient found in cannabis — one that doesn't get users high — as a medication for rare, hard-to-treat seizures in children. If successful, the company's liquid formula would be the first government-approved drug derived from the cannabis plant in the U.S.

The Food and Drug Administration's approval would technically limit the treatment to a small group of epilepsy patients. But doctors would have the option to prescribe it for other uses and it could spur new pharmaceutical research and interest into other cannabis-based products. Man-made versions of a different marijuana ingredient have previously been approved for other purposes.

The FDA posted its review of the experimental medication Epidiolex ahead of a public meeting Thursday when a panel of outside experts will vote on the medicine's safety and effectiveness. It's a non-binding recommendation that the FDA will consider in its final decision by late June.

Patients taking the treatment had fewer seizures, according to the FDA's internal review posted online. Scientists concluded that GW Pharmaceutical's submission "appears to support approval" despite some potential side effects including risks of liver injury.

More than two dozen states allow marijuana use for a variety of ailments, but the FDA has not approved it for any medical use. In 2016, the agency recommended against easing federal restrictions on marijuana. The U.S. continues to classify marijuana as a high-risk substance with no medical use, alongside other illicit drugs like heroin and LSD.

For years, desperate patients and parents have pushed for wider access to medical marijuana products for a host of conditions including pain, post-traumatic stress disorder and epilepsy, with only anecdotal stories and limited studies on their side.

But studies conducted by GW Pharmaceuticals have begun to change that picture.

Across three studies involving more than 500 patients, Epidiolex generally cut the number of monthly seizures by about 40 percent, compared with reductions between 15 and 20 percent for patients taking a dummy medicine.

Most patients in the study were already taking at least three other medications to try and control their seizures.

Epidiolex is essentially a pharmaceutical-grade version of cannabidiol, or CBD oil, which some parents have used for years to treat children with epilepsy. CBD is one of more than 100 chemicals found in the cannabis plant and it doesn't contain THC, the ingredient that gives marijuana its mind-altering effect.

CBD oil is currently sold online and in specialty shops across the U.S., though its legal status remains murky. Most producers say their oil is made from hemp, a plant in the cannabis family that contains little THC and can be legally farmed in a number of states for clothing, food and other uses.

A doctor who treats children with epilepsy says it's important to have an FDA-approved version of CBD.

"I think it needs to be approved because everyone is using it across the internet without knowing the safety ... and no one is watching the interactions with other drugs," said Dr. Joan Conry of Children's National Health System in Washington, who was not involved in the studies.

Conry and other researchers say it's not yet clear why CBD reduces seizures in some patients.

GW Pharmaceuticals makes its drug from cannabis plants that are specially bred to contain high levels of CBD. It's seeking approval for two rare forms of childhood epilepsy — Dravet and Lennox-Gastaut syndromes.

Common side effects included diarrhea, vomiting, fatigue and sleep problems. FDA reviewers flagged a more serious issue with potential liver injury, but said doctors could manage the risk by monitoring patients' enzyme levels.

Recs

0
Member Avatar wadethefred (54.34) Submitted: 12/2/2017 8:56:44 PM : Underperform Start Price: $126.99 GWPH Score: -14.44

valuation is absurd. 3B in mkt cap with 10M in revenue and of course the company is losing money. marijuana market is over-hyped as everyone is trying to buy into a pure play company as governments ease restrictions on marijuana.

Leaderboard

Find the members with the highest scoring picks in GWPH.

Score Leader

headyinvestor

headyinvestor (60.24) Score: +373.51

The Score Leader is the player with the highest score across all their picks in GWPH.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
headyinvestor 60.24 11/8/2013 Outperform 5Y $28.33 +430.25% +56.74% +373.51 0 Comment
freddybefreddy < 20 10/9/2013 Outperform 5Y $28.31 +430.63% +66.80% +363.82 0 Comment
Angko 65.47 10/23/2013 Outperform 3M $29.01 +417.82% +58.21% +359.62 1 Comment
HarryCaraysGhost 86.66 12/12/2013 Outperform 5Y $30.96 +385.21% +54.81% +330.39 1 Comment
Docendo 64.29 12/9/2013 Outperform 3Y $31.18 +381.78% +52.56% +329.22 0 Comment
xBubbaGumpShrimp 27.35 10/28/2013 Outperform 5Y $31.25 +380.70% +57.23% +323.47 0 Comment
KyleHansen 54.06 12/24/2013 Outperform 3Y $35.53 +322.80% +51.20% +271.60 0 Comment
heirapparent 74.68 11/29/2013 Outperform 5Y $35.88 +318.67% +52.53% +266.15 0 Comment
whatthree16 68.40 11/27/2013 Outperform 5Y $36.65 +309.88% +52.64% +257.23 0 Comment
velo15 < 20 3/1/2016 Outperform 5Y $37.92 +296.15% +39.64% +256.51 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackJimCramer 85.47 5/31/2017 Underperform 3W $98.61 +52.34% +14.56% -37.78 0 Comment
TrackJimCramer 85.47 9/26/2016 Outperform 3W $126.06 -21.78% +12.69% -34.46 5/31/2017 @ $98.61 0 Comment
TrackJimCramer 85.47 11/10/2015 Underperform 3W $85.61 +47.25% +2.73% -44.52 9/26/2016 @ $126.06 0 Comment
TrackPiperJaff 87.50 6/30/2014 Outperform NS $100.66 +49.24% +41.32% +7.92 0 Comment
TrackJimCramer 85.47 5/20/2014 Outperform 3W $67.83 +26.21% +11.20% +15.02 11/10/2015 @ $85.61 0 Comment

Featured Broker Partners


Advertisement